H7N9 pandemic preparedness: A large-scale production of a split inactivated vaccine

• Published in: Biochemical and biophysical research communications Vol. 545; pp. 145 - 149
• Main Authors: Adami, Eduardo Alfredo, Chavez Rico, Stefanni Liliane, Akamatsu, Milena Apetito, Miyaki, Cosue, Raw, Isaías, de Oliveira, Dourival, Comone, Priscila, Oliveira, Ricardo das Neves, Sarno de Oliveira, Maria Leonor, Estima Abreu, Patrícia Antônia, Takano, Carolina Yumi, Meros, Maurício, Soares-Schanoski, Alessandra, Lee Ho, Paulo
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 19.03.2021
• Subjects: Adjuvant; Animals; Antigens, Viral - biosynthesis; Antigens, Viral - immunology; Drug Compounding - methods; Drug Compounding - statistics & numerical data; Drug Industry - standards; Female; H7N9 pandemic; Humans; Inactivated vaccine; Influenza A Virus, H7N9 Subtype - immunology; Influenza vaccine; Influenza Vaccines - biosynthesis; Influenza Vaccines - immunology; Influenza Vaccines - isolation & purification; Influenza, Human - immunology; Influenza, Human - prevention & control; Influenza, Human - virology; Mice; Mice, Inbred BALB C; Pandemic preparedness; Pandemics - prevention & control; Vaccines, Inactivated - biosynthesis; Vaccines, Inactivated - immunology; Vaccines, Inactivated - isolation & purification; Adjuvant; Influenza vaccine; Pandemic preparedness; Inactivated vaccine; H7N9 pandemic

In March 2013 it was reported by the World Health Organization (WHO) the first cases of human infections with avian influenza virus A (H7N9). From 2013 to December 2019, 1568 cases have been reported with 616 deaths. H7N9 infection has been associated with high morbidity and mortality rates, and vac...